Removing barriers to appropriate migraine treatment: Formulary limitations and triptan package size

Headache

Volumn 45, Issue 9, 2005, Pages 1250-1254

  Silberstein, Stephen D ^a,d   Dodick, David ^b   Kesslick, Jim ^c  

^a JEFFERSON HEADACHE CENTER   (United States)

^b MAYO CLINIC   (United States)

^c Gibbon Building ^*

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Formulary; Managed care; Migraine; Pharmacoeconomics; Triptans

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; SEROTONIN AGONIST;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE PLANNING; HUMAN; LONG TERM CARE; MANAGED CARE ORGANIZATION; MIGRAINE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; DRUG PACKAGING; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; METHODOLOGY; PUBLICATION; STANDARD;

DRUG PACKAGING; FORMULARIES; HEALTH CARE RATIONING; HEALTH SERVICES ACCESSIBILITY; HUMANS; MANAGED CARE PROGRAMS; MIGRAINE DISORDERS; SEROTONIN AGONISTS;

EID: 33644873543     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.00250.x     Document Type: Review

References (17)

1. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849.
2. The economics of migraine. Based on a presentation by Stuart O. Schweitzer, PhD. Am J Manag Care. 1999;5:S91-S98.
3. Gerth WC, Carides GW, Dasbach EJ, Visser WH, Santanello NC. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics. 2001;19:197-206.
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
5. Brixner D, Brandes J. Migraine matters: the role of triptans in relieving the burden in managed care. J Manag Care Pharm. 2004:S2-S12.
6. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-2454.
7. Matchar D, Young W, Rosenberg J, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacologic management of acute attacks. Am Acad Neurol. 2000:1-58.
8. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache. 2002;42:28-31.
9. Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78:1214-1222.
10. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache. 2003;43:1075-1079.
11. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache. 1998;38:173-183.
12. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
13. Lassen D, Boreen D. Impact of quantity limits on migraine medications: analysis of utilization and total health care costs in a midwestern health plan. J Manag Care Pharm. 2001;7:132.
14. Mauskop A, Dodick D, Freitag F, Loder E. Advances in migraine prophylaxis [Monograph on the Internet]. National Headache Foundation; [Cited 2004 October 6]. Available from http://www.headaches.org. 2001.
15. Adelman JU, Adelman LC, Freeman MC, Von Seggern RL, Drake J. Cost considerations of acute migraine treatment. Headache. 2004;44:271-285.
16. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41248-41256.
17. Silberstein SD, Elkind AH, Schreiber C, Keywood C. Randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.